Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

The football legend, 44, has revealed another huge milestone for his family, announcing that his youngest son has taken part ...

Neurocrine Biosciences appoints Andrew Ratz as senior VP of drug development amid expanding R&D efforts. The move follows FDA ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...